The
Semax (
Met-Glu-
His-Phe-Pro-Gly-Pro)
peptide is a synthetic
melanocortin derivative that is used in the treatment of
ischemic stroke. Previously, studies of the molecular mechanisms underlying the actions of
Semax using models of
cerebral ischemia in rats showed that the
peptide enhanced the transcription of
neurotrophins and their receptors and modulated the expression of genes involved in the immune response. A genome-wide
RNA-Seq analysis revealed that, in the rat transient
middle cerebral artery occlusion (tMCAO) model,
Semax suppressed the expression of inflammatory genes and activated the expression of
neurotransmitter genes. Here, we aimed to evaluate the effect of
Semax in this model via the brain expression profiling of key
proteins involved in
inflammation and cell death processes (
MMP-9, c-Fos, and JNK), as well as neuroprotection and recovery (CREB) in
stroke. At 24 h after tMCAO, we observed the upregulation of active CREB in subcortical structures, including the focus of the ischemic damage; downregulation of MMP-9 and c-Fos in the adjacent frontoparietal cortex; and downregulation of active JNK in both tissues under the action of
Semax. Moreover, a regulatory network was constructed. In conclusion, the suppression of inflammatory and cell death processes and the activation of recovery may contribute to the neuroprotective action of
Semax at both the transcriptome and
protein levels.